

CLINICAL COURSE AND OUTCOME OF COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME: DATA FROM A NATIONAL REPOSITORY

Ali A. El-Solh, MD, MPH ¹⁻³; Umberto G. Meduri, MD⁴; Yolanda Lawson, MS¹; Michael Carter, PharmD¹, Kari A. Mergenhagen, PharmD¹

¹VA Western New York Healthcare System, Buffalo, NY.; ²Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine; ³Department of Epidemiology and Environmental Health, State University of New York at Buffalo School of Medicine and Biomedical Sciences and School of Public Health and Health Professions; Buffalo, NY; and ⁴Memphis VA Medical Center, Memphis, Tennessee

Please address any correspondence and reprint request to:

Ali El Solh, MD, MPH
VA Western New York Healthcare System
3495 Bailey Avenue
Buffalo, NY 14215
Tel (716) 862-7392
Fax (716) 862-6526
Email: solh@buffalo.edu

Summary conflict of interest statements: AES has received grant support from the Department of Veterans Affairs. UGM has received grant support from the Department of Veterans Affairs. YL declares no conflict to report. MC declares no conflict to report. KM declares no conflict to report.

Funding information: None

Acknowledgments: The views expressed in this manuscript do not communicate an official position of the Department of Veterans Affairs.

ABSTRACT

Background: Mortality attributable to coronavirus disease-19 (COVID-19) 2 infection occurs mainly through the development of viral pneumonia-induced acute respiratory distress syndrome (ARDS).

Research Question: The objective of the study is to delineate the clinical profile, predictors of disease progression, and 30-day mortality from ARDS using the Veterans Affairs Corporate Data Warehouse.

Study Design and Methods: Analysis of a historical cohort of 7,816 hospitalized patients with confirmed COVID-19 infection between January 1, 2020, and August 1, 2020. Main outcomes were progression to ARDS and 30-day mortality from ARDS, respectively.

Results: The cohort was comprised predominantly of men (94.5%) with a median age of 69 years (interquartile range [IQR] 60-74 years). 2,184 (28%) were admitted to the intensive care unit and 643 (29.4%) were diagnosed with ARDS. The median Charlson Index was 3 (IQR 1-5). Independent predictors of progression to ARDS were body mass index (BMI) ≥ 40 kg/m², diabetes, lymphocyte counts $< 700 \times 10^9/L$, LDH > 450 U/L, ferritin > 862 ng/ml, C-reactive protein > 11 mg/dL, and D-dimer > 1.5 ug/ml. In contrast, the use of an anticoagulant lowered the risk of developing ARDS (OR 0.66 [95% CI 0.49-0.89]. Crude 30-day mortality rate from ARDS was 41% (95% CI 38%-45%). Risk of death from ARDS was significantly higher in those who developed acute renal failure and septic shock. Use of an anticoagulant was associated with two-fold reduction in mortality. Survival benefit was observed in patients who received corticosteroids and/or remdesivir but there was no advantage of combination therapy over either agent alone.

Conclusions: Among those hospitalized for COVID-19, nearly one in ten progressed to ARDS. Septic shock, and acute renal failure are the leading causes of death in these patients. Treatment with either remdesivir and corticosteroids reduced the risk of mortality from ARDS. All hospitalized patients with COVID-19 should be placed at a minimum on prophylactic doses of anticoagulation.

Keywords: COVID-19, ARDS, mortality, anticoagulation

INTRODUCTION

Since it was declared a pandemic, the coronavirus disease 2019 (COVID19) had a dramatic effect on world health and daily life. The disease ranks now as the third leading cause of death in the United States — ahead of accidents, injuries, lung disease, diabetes, and Alzheimer's disease.¹ As of August 20, 2020 there were nearly 820,000 deaths attributed to COVID-19 with greater than 20 million people infected with the virus.²

The acute respiratory distress syndrome (ARDS) represents the most serious complication of COVID-19 infection with an estimated mortality ranging between 26.4% and 94%.^{3, 4} Recent publications from China, Italy and United States have described an atypical manifestation of the disease characterized by an exaggerated inflammatory and increased incidence of shock.⁵⁻⁷ Others have reported distinct phenotype characterized by higher respiratory compliance despite extensive radiographic abnormalities.⁸ Therapeutic regimens have included prone positioning, extracorporeal membrane oxygenation (ECMO) and anti-inflammatory agents.⁹ Yet none of these approaches have resulted in a mortality benefit when studied in a robust manner.

Because treatment options for COVID-19 ARDS are limited, there is an interest in identifying at-risk patients for early intervention strategies to alter the clinical course and progression of the disease. Several studies have identified factors associated with disease progression and mortality in COVID-19 patients.^{3, 4, 10, 11} These studies have been limited by smaller sample sizes and inconsistencies in their validity when applied to other cohorts. The aim of this study was to delineate pre-existing risk factors associated with developing ARDS and to explore treatment outcomes of ARDS related to COVID-19.

METHODS

Data Source

This study applied a cohort design to historical data available in the VA Corporate Data Warehouse (CDW). The CDW is a national repository encompassing data from Veterans Health Administration (VHA) clinical and administrative systems.¹² Over 200 Veterans Health Information Systems and Technology Architecture (VistA) modules are responsible for generating CDW data. At point of care, data are entered into VistA systems by way of manual entry, barcode scanning, or through automated equipment. These data are then uploaded into the CDW and organized into relational format by logical domains. Data domains utilized in this study included: outpatient, inpatient, and pharmacy. The local Institutional Review Board deemed the current research as exempt based on federal regulation 45CFR46.

Study population

All patients who were reportedly 18 years of age or older at any point between January 1, 2020, and August 1, 2020, were identified in the CDW. The cohort study is comprised of patients who had tested positive for COVID-19 confirmed by reverse transcription PCR assay obtained from nasal and pharyngeal swab. The date at which the test was recorded as positive is referred to as *the index date*.¹³ We used the International Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)¹⁴ linked to each hospitalization to identify all adult records with ARDS (ICD-10 J80). Cases with documented coinfection with other viral pathogens were excluded from the analysis. In case of multiple admissions, only the date of the first hospitalization was considered. For patients who required re-intubation, only the date of the first intubation was entered into the analysis.

The following variables were extracted: patient and hospital demographics, comorbid conditions and list of medications recorded during the 2-year period on or before the index date, documented symptoms occurring on or within 30 days prior to the index date, laboratory data within 10 days of the index date, admission and discharge dates, treatment modalities, and discharge status. We categorized patients into five groups according to the definitions of the

National Institutes of Health (18). We used the Charlson Comorbidity Index¹⁵ (age excluded) provided by the CDW to derive the prevalence of comorbidities in our sample. The list of comorbid conditions was based on the ICD-10 diagnosis recorded in the VA Computerized Patient Record System during the 2-year period preceding the index date. To avoid misclassification bias, we excluded all records with acute respiratory failure that could have been attributed to acute cardiogenic pulmonary edema (ICD-10 J81). To further improve the precision and internal validity, records with mechanical ventilation prior to index date were excluded from the cohort.

Outcomes

The study outcomes were progression to ARDS within 60 days of the index date, and 30-day mortality of those who developed ARDS from COVID-19. Death is captured from the VA Beneficiary Identification and Records Locator System, Social Security Administration death files, and the Department of Defense.¹⁶

Statistical analysis

Data are reported as mean (standard deviation [SD]) or median (interquartile range [IQR]). Continuous variables were compared using Student's t test or the Mann-Whitney U or Wilcoxon test based on normality of data distribution using the Kolmogorov-Smirnov goodness-of-fit test. For variables with more than 2 categories, analysis of variance was performed to identify significant differences among categories. A χ^2 test was performed as appropriate for categorical variables. Clinically significant variables with a p value <0.1 at univariate analysis were included in the multivariate logistic regression analysis. We used logistic regression to quantify odds ratio (OR), standard error, and 95% confidence interval (CI) for variables that had significance among the groups for developing ARDS. Thresholds for age, BMI, absolute lymphocyte count, LDH, CRP, and D-dimer level were chosen based on previous COVID-19 studies.^{17, 18} We excluded the variables that had an r value of >0.4 in the factor analysis from multivariate regression. Bivariate Cox proportional

hazards models were used to identify independent risk factors for 30-day mortality among patients with ARDS. Time-to-event was defined as the time from date of respiratory support to discharge status. Mantel-Cox (log-rank) tests were performed to compare survival curves. Independent variables with $p < 0.05$ in univariate analysis were selected for multivariate Cox proportional hazard ratio (HR) models. Analysis was conducted in Stata MP version 15 (StataCorp). Statistical significance was set at $P < .05$, and all tests were 2-tailed.

RESULTS

Demographics

A total of 7,816 hospitalized patients with confirmed COVID-19 were included in this database, with a median follow-up of 13 days (IQR 7-23 days). The median age of the study cohort was 69 years (IQR 60–74 years). The sample was predominantly male (94.5%) with 45% White, 42% Black and 12% Latinos. The mean BMI in the study cohort was 29.5 ± 7.1 kg/m²; 1,657 (21.2%) had normal BMI, 3.2% were underweight, 30.1% overweight, 23.8% obese, and 19.6% morbidly obese. Forty-seven percent had at least three comorbidities. Hypertension, diabetes mellitus, and chronic heart disease were the most common underlying comorbidities at 73%, 48%, and 29% respectively. The median Charlson Comorbidity index of the study population was 3 (IQR 1-5). In total, 2,184 (28%) patients were admitted to the ICU of whom 643 (29.4%) met the diagnosis of ARDS. Baseline clinical characteristics are summarized in table 1. COVID-19 patients who developed ARDS had a higher body mass index ($\text{BMI} \geq 40$ kg/m²) (OR 1.72 [95% CI 1.32-2.24]; $p < 0.001$), and were more likely to be African Americans (OR 1.29 [95% CI 1.11-1.52]; $p = 0.002$). Although the burden of comorbidities was similar between the two groups, both hypertension (OR 1.36 [95% CI 1.11-1.65]; $p = 0.002$) and diabetes (OR 1.35 [95% CI 1.15-1.59]; $p < 0.001$) were significantly associated with ARDS. The odds of developing ARDS did not vary significantly with age

(age \geq 70 years) (OR 0.92 [95% CI 0.79-1.09]; p=0.37), male sex (OR 1.2 [95% CI 0.82-1.76]; p=0.34), or smoking history (1.16 [95% CI 0.89-1.42]; p=0.28).

In bivariate logistic regression analysis, the use of prednisone prior to index date (OR 1.44 [95% CI 0.98-2.12]; p=0.06) showed a trend, although not significant, toward increased risk for ARDS while the use of an anticoagulant (OR 0.69 [95%CI 0.59-0.82]; p<0.001) or a nebulized beta-agonist (OR 0.78 [95% CI 0.62-0.97]; p=0.027) prior to index date were protective against developing ARDS. As for patients receiving angiotensin converting enzyme inhibitors (OR 1.09 [95% CI 0.92-1.29]; p=0.29) or statins (OR 0.92 [95% CI 0.86-1.38]; p=0.31), the odds of progression to ARDS were comparable between both groups.

Clinical presentation

The first symptoms of COVID-19 were reported 5 days (3-7 days) before hospital admission. The most commonly self-reported symptoms in the study cohort at onset of illness were fever (n=4,057 [52.0%]), cough (n=1,742 [22.3%]), dyspnea (n=2,413 [31.1%]), and diarrhea (n=669 [8.6%]). The median time from hospital admission to ICU was 2 days (IQR 0-4 days). Early ICU admission (days 0-2) was observed notably in those with higher comorbidity index (CCI 4 (IQR 2-7)). Table 2 depicts a comparison between the clinical manifestations and laboratory findings of patients with ARDS and those without ARDS. Bivariate regression analysis found that fever (OR 1.64 [95% CI 1.38-1.94]; p<0.001), cough (OR 1.41 [95%CI 1.18-1.69]; p<0.001), and dyspnea (OR 1.92 [95% CI 1.64-2.27]; p<0.001) were most often reported in patients who developed ARDS than those who did not. Patients with ARDS were more likely to have lower lymphocyte counts (absolute lymphocyte count $\leq 0.7 \times 10^9/L$) (OR 1.74 [95% CI 1.47-2.07]; p<0.001), lower platelets (platelets $<135 \times 10^9/L$) (OR 1.26 [95%CI 1.01-1.57]; p=0.04), and higher LDH (LDH>450 U/L) (OR 3.25 [95% CI 2.64-4.0]; p<0.001) compared to non ARDS. Similarly, elevated levels for biomarkers including CRP (CRP>11 mg/dL) (OR 1.98 [95% CI 1.61-2.44]; p<0.001), ferritin (ferritin >862 ng/mL) (OR 2.1 [95% CI 1.75-2.52]; p<0.001), and D-dimer levels

(D-dimer>1.5 ug/mL) (OR 1.7 [95% CI 1.41-2.05]; p<0.001) were associated with greater risk of developing ARDS.

Multivariate analysis identified BMI \geq 40 kg/m² (OR 1.77 [95% CI 1.17-2.68]; p=0.007), diabetes (OR 1.36 [95% CI 1.03-1.79]; p=0.03), lymphocyte counts<700109/L (OR 1.56 [95% CI 1.19-2.06]; p=0.001), LDH>450 U/L (OR 2.42 [95% CI 1.77-3.26]; p<0.001), ferritin >862 ng/ml (OR 1.43 [95% CI 1.07-1.91]; p=0.01), CRP>11 mg/dL (OR 1.43 [95% CI 1.09-1.88]; p<0.001), and D-dimer >1.5 ug/ml (OR 1.45 [95% CI 1.09-1.93]; p=0.009) to be associated with progression to ARDS (Figure 1). In contrast, the use of an anticoagulant prior to index date (OR 0.66 [95% CI 0.49-0.89]; p=0.06) lowered the risk of developing ARDS.

ARDS clinical course and outcomes

Of the 643 COVID-19 patients who met the definition of ARDS, 464 (72%) were placed on mechanical ventilation (MV). The time from COVID -19 diagnosis to intubation was 12 days (IQR 8-20). Of those who did not receive MV initially, 98 (15%) had been placed on either continuous positive airway pressure or bi-level positive airway pressure and 76 (12%) on high flow nasal oxygen. Prone positioning was applied in 167 (26%) patients at least once during the ICU stay, and only two patients underwent ECMO therapy. A total of 142 (22%) patients developed renal failure requiring renal replacement therapy and 52 (8%) were treated for septic shock. Two hundred sixty-five (41%) died within 30 days. Table 3 displays the demographics and clinical characteristics of ARDS survivors and ARDS non-survivors from COVID-19 (Table 3). In a univariate Cox regression model, age>70 years (HR 2.35 [95% CI 1.82-3.03]; p<0.001), hypertension (HR 1.41 [95% CI 1.02-1.93]; p=0.04), chronic heart disease (HR 1.6 [95%CI 1.20-2.0]; p=0.001), and Charlson comorbidity index (HR 1.08 [95% CI 1.04-1.12], p<0.001) were independently associated with ARDS mortality. In addition, the risk of mortality among ARDS patients was significantly higher in those who developed acute renal failure (HR 2.0 [95% CI 1.45-2.77]; p<0.001) and septic shock post index date (HR 1.78 [95% CI 1.36-2.32]; p<0.001). In terms of treatment, administering

corticosteroids (HR 0.61 [95% CI 0.47-0.78]; $p < 0.001$) and remdesivir (HR 0.53 [95% CI 0.39-0.7], $p < 0.001$) contributed to improved survival from COVID-19-related ARDS. Similarly, the use of an anticoagulant post index date (HR 0.47 [95% CI 0.25-0.89]; $p = 0.02$) resulted in two-fold decrease in the risk of dying (Figure 2). Of interest, administration of hydroxychloroquine (HR 1.18 [95% CI 0.93-1.51]; $p = 0.17$) or antibiotics (HR 0.81 [95% CI 0.58-1.13]; $p = 0.21$) did not alter the risk of mortality among patients with ARDS. Kaplan–Meier survival analysis showed a 30-day survival benefit from remdesivir ($p = 0.001$) and corticosteroids ($p = 0.006$) compared to those who received neither of these agents. However, there was no significant difference in survival between remdesivir and corticosteroids ($p = 0.23$) nor with the combination of both agents versus corticosteroids alone ($p = 0.07$) or versus remdesivir alone ($p = 0.77$), respectively (Figure 3). In multivariate Cox proportional hazard regression model, the following parameters at admission were predictive of 30-day mortality from ARDS: age > 70 years (HR 2.14 [95% CI 1.65-2.77]; $p < 0.001$), acute renal failure (HR 1.83 [95% CI 1.28-2.59]; $p = 0.001$), and septic shock (HR 1.54 [95% CI 1.16-2.06]; $p = 0.002$). Remdesivir (HR 0.71 [95% CI 0.52-0.97]; $p = 0.03$), corticosteroids treatment (HR 0.73 [95% CI 0.54-0.98]; $p = 0.04$), and use of an anticoagulant post index date (HR 0.35 [95% CI 0.22-0.55]; $p < 0.001$) were linked to reduced 30-day mortality from ARDS (Figure 4).

DISCUSSION

Our report represents one of the largest multicenter cohorts of patients who developed ARDS from COVID-19 infection. Among those requiring intensive care for COVID-19, nearly a third progressed to ARDS and among those who developed ARDS, 41% succumbed to the disease. Morbid obesity, diabetes, lymphopenia and cellular driven inflammatory and coagulation activation on hospital admission emerged as predisposing factors for severe respiratory disease while mortality from ARDS was associated with higher burden of comorbidities, septic shock, and acute renal failure. Our study adds to the existing literature by identifying a potential benefit of

anticoagulants against ARDS progression for those who were prescribed these agents prior to being infected with COVID-19. Because of the coagulation propensity in these patients, administration of an anticoagulant post-index date appeared to reduce the risk of mortality from ARDS. Similar survival benefit on ARDS mortality was also noted for corticosteroids and remdesivir treatment but not for hydroxychloroquine or nebulized beta-agonists.

In our cohort, the time from onset of illness or symptoms to ICU admission ranged from 5 to 12 days. This period is comparable to those observed in other studies^{4, 10, 19, 20}. Notably, patients who had higher comorbidity index and more deranged laboratory parameters were admitted earlier to the ICU. Among the strongest risk factors related to progression to ARDS included morbid obesity. In similarity to the H1N1 epidemic, early epidemiological studies showed that obesity worsens the complications of COVID-19 infection²¹⁻²⁴. The Centers for Disease Control and Prevention has identified morbid obesity (BMI ≥ 40 kg/m²) as a clinical risk factor for worse prognosis and higher mortality²⁵. In our study, we found that for each 1 kg/m² increase in BMI, the risk of severe COVID-19 increased by 3%. Most strikingly, morbid obesity resulted in nearly two times greater risk of developing ARDS upon infection, a rate comparable to those infected with H1N1 epidemic^{26, 27}. Although the pathophysiology underlying COVID-19-infection has not been completely elucidated, there are several mechanisms that may predispose obese patients to progress to a more severe form of the disease including: (1) increased expression of angiotensin-converting enzyme 2 in the pulmonary vascular system which acts as a portal entry for virus invasion²⁸, (2) accumulation of pro-inflammatory cells in the adipose tissue including macrophages, dendritic cells, and Th1 lymphocytes responsible for increased release of pro-inflammatory cytokines such as IL-6 and CRP²⁸ (3) higher burden of comorbidities such as diabetes, a recognized risk factor for COVID-19 disease progression and worse prognosis. Interestingly, morbid obesity was not associated with mortality from ARDS in our study and this observation could be related to the obesity paradox reported in critically ill obese patients²⁹.

Other risk factors that we have identified in our analysis indicative of progression to ARDS comprised lymphopenia, LDH, CRP, D-dimer, and ferritin. These biomarkers have consistently been reported in recent epidemiologic studies of COVID-19 infection as prognostic indicators of poor outcomes.^{4, 24, 30, 31} Not surprisingly, these factors, alone or in combination, were entered into several predictive nomograms used to stratify disease severity.³²⁻³⁴ More importantly, these biomarkers are thought to reflect active and ongoing injury to the underlying parenchymal and vascular beds within and outside the lungs.³⁵ The exuberant response of proinflammatory cytokines, what has been labeled as a cytokine storm, results in increased vascular hyperpermeability, activation of coagulation pathways, and eventually multiorgan failure including ARDS.³⁶ A recent observational study involving 183 cases of coronavirus pneumonia patients revealed significantly higher D-dimers, longer prothrombin time and activated partial thromboplastin time on admission in non survivors compared to survivors with more than 70% of non survivors meeting the criteria of disseminated intravascular coagulation (DIC) during hospitalization.³⁷ The current study provides a credence for such hypothesis in showing that not only use of an anticoagulant before the index date may limit the progression of the disease but also prescribing an anticoagulant post-index date may improve survival from ARDS. Our results are further corroborated by a recent retrospective study of 4,389 patients hospitalized for COVID-19 showed that compared to no anticoagulation, therapeutic and prophylactic anticoagulation were associated with lower in-hospital mortality and intubation.³⁸ We should indicate that the present findings are limited in terms of determining the most effective type of anticoagulant or the optimal dose to administer in these cases because the database, we had access to, did not contain granular information on this question. We recognize that data on the potential beneficial effect of anticoagulation in COVID-19 remains very scarce. Nonetheless, due to the high risk of DIC and venous thromboembolism, hospitalized COVID-19 patients should receive thromboprophylaxis at a minimum, as suggested by the recent guidelines for the prevention, diagnosis, and treatment of VTE in patients with COVID-19.³⁹

At the present, therapeutic interventions for COVID-19 are limited in scope and regimens administered for COVID-19 ARDS have been based in majority on anecdotal reports, expanded use of existing or experimental drugs, or on trials conducted on ARDS patients prior to the pandemic. We have observed no significant benefit of corticosteroids before the index date on disease progression but there was a significant survival benefit post index date for those who developed ARDS. This benefit persisted after adjustment for several covariates. In line with these findings, at least three published randomized clinical trials demonstrated that judicious use of corticosteroids has shown to improve several outcomes of severe COVID-19 infection⁴⁰⁻⁴² including reduction of duration of hospital stay, ventilator-free days, and death. Further analysis of the steroids dosing and frequency of administration is needed to estimate the risk/benefit ratio of such an intervention however this information was not available at the time we have accessed this database.

Remdesivir, a recently FDA approved agent for the treatment of COVID-19 in patients 12 years of age or older with pneumonia who require supplemental oxygen,⁴³ showed similar survival advantage in COVID-19 ARDS even after taking other covariates into consideration. Interestingly, in the clinical trial under which the Emergency Use Authorization was granted, remdesivir resulted in shortening time to recovery in adults hospitalized with COVID-19 and evidence of lower respiratory tract infection, but it did not result in increased survival compared to the placebo group at day 14.⁴⁴ It should be noted that the participants in the remdesivir trial were younger, leaner, and had fewer underlying comorbidities than the current sample which may have lessened the mortality difference between the active and control group. Of significance, the combination of corticosteroids and remdesivir did not improve the chance of survival over either of these agents alone. This observation was somewhat surprising given that the mechanism of action of these two agents are dissimilar. It is plausible that curbing viral replication with remdesivir may dampen the upregulation of cytokines downstream limiting the effect of corticosteroids. Additional trials are needed to verify this hypothesis.

A major strength of the study stems from the fact that the data originated from a large healthcare system that deploys an electronic medical record for the collection and storage of patient health information making variability among regional healthcare centers less influential on the overall outcomes of the study. Among the limitations include the inherent biases of retrospective analyses involving large administrative databases, such as confounding effects and coding errors. Since the VA places less emphasis on billing, this may impact the prevalence of the condition under examination. Second, the predominance of male representation in this cohort may limit the applicability of the findings to other groups. Third, we did not collect data on do-not-resuscitate or do-not-intubate orders or the availability of palliative care for patients. These factors may have contributed to differing rates of intubation and ICU admission, and thus mortality from ARDS.

Conclusions

In this large cohort of hospitalized patients with COVID-19, morbid obesity and elevated proinflammatory markers were associated with progression to ARDS while advanced age, septic shock, and acute renal failure predicted poor prognosis in those with ARDS. A higher survival rate from ARDS was observed in those who received prophylactic or therapeutic anticoagulation. Remdesivir and corticosteroids offered also a survival advantage in those being treated for ARDS. Rigorous randomized clinical trials are urgently needed to evaluate whether a combination strategy of available treatment modalities may impart further survival advantage over existing monotherapies.

REFERENCES

1. Statistics NCfH. Leading Causes of Death. *Centers for Disease Control and Prevention*. Available at: <https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm>. Accessed September 30, 2020.
2. COVID-19 dashboard. *John Hopkins Center for Systems Science and Engineering*. Available at: <https://coronavirus.jhu.edu/map.html>, August 20, 2020.
3. Azoulay E, Fartoukh M, Darmon M, et al. Increased mortality in patients with severe SARS-CoV-2 infection admitted within seven days of disease onset. *Intensive Care Med*. Sep 2020;46(9):1714-1722.
4. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*. Jul 1 2020;180(7):934-943.
5. Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. *Nature*. Jul 2020;583(7816):437-440.
6. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. Mar 28 2020;395(10229):1033-1034.
7. Sinha P, Matthay MA, Calfee CS. Is a "Cytokine Storm" Relevant to COVID-19? *JAMA Intern Med*. Jun 30 2020.
8. Rello J, Storti E, Belliato M, Serrano R. Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers. *Eur Respir J*. May 2020;55(5).
9. Fragkou PC, Belhadi D, Peiffer-Smadja N, et al. Review of trials currently testing treatment and prevention of COVID-19. *Clin Microbiol Infect*. Aug 2020;26(8):988-998.
10. Wendel Garcia PD, Fumeaux T, Guerci P, et al. Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. *EClinicalMedicine*. Aug 2020;25:100449.

11. Jang JG, Hur J, Choi EY, Hong KS, Lee W, Ahn JH. Prognostic Factors for Severe Coronavirus Disease 2019 in Daegu, Korea. *J Korean Med Sci.* Jun 15 2020;35(23):e209.
12. Fihn SD, Francis J, Clancy C, et al. Insights from advanced analytics at the Veterans Health Administration. *Health Aff (Millwood).* Jul 2014;33(7):1203-1211.
13. Department of Veterans Affairs, Office of Research and Development. COVID-19 Shared Data Resource. Available at:

https://vhacdwdwhweb100.vha.med.va.gov/phenotype/index.php/COVID-19:Shared_Data_Resource. Accessed September 30, 2020.
14. Organization WH. *International Statistical Classification of Diseases, Tenth Revision (ICD-10)*. 1992.
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40(5):373-383.
16. Sohn MW, Arnold N, Maynard C, Hynes DM. Accuracy and completeness of mortality data in the Department of Veterans Affairs. *Popul Health Metr.* Apr 10 2006;4:2.
17. Feld J, Tremblay D, Thibaud S, Kessler A, Naymagon L. Ferritin levels in patients with COVID-19: A poor predictor of mortality and hemophagocytic lymphohistiocytosis. *Int J Lab Hematol.* Aug 13 2020.
18. Poggiali E, Zaino D, Immovilli P, et al. Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. *Clin Chim Acta.* Oct 2020;509:135-138.
19. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA.* Apr 28 2020;323(16):1574-1581.
20. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ.* Mar 26 2020;368:m1091.

21. Anderson MR, Geleris J, Anderson DR, et al. Body Mass Index and Risk for Intubation or Death in SARS-CoV-2 Infection: A Retrospective Cohort Study. *Ann Intern Med*. Jul 29 2020.
22. Simonnet A, Chetboun M, Poissy J, et al. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. *Obesity (Silver Spring)*. Jul 2020;28(7):1195-1199.
23. Lighter J, Phillips M, Hochman S, et al. Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission. *Clin Infect Dis*. Jul 28 2020;71(15):896-897.
24. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *BMJ*. May 22 2020;369:m1966.
25. Groups at higher risk for severe illness. *Centers for Disease Control and Prevention Coronavirus disease 2019 (COVID-19)*. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html>. Accessed September 24,2020.
26. Fezeu L, Julia C, Henegar A, et al. Obesity is associated with higher risk of intensive care unit admission and death in influenza A (H1N1) patients: a systematic review and meta-analysis. *Obes Rev*. Aug 2011;12(8):653-659.
27. Louie JK, Jean C, Acosta M, Samuel MC, Matyas BT, Schechter R. A review of adult mortality due to 2009 pandemic (H1N1) influenza A in California. *PLoS One*. Apr 5 2011;6(4):e18221.
28. Kruglikov IL, Scherer PE. The Role of Adipocytes and Adipocyte-Like Cells in the Severity of COVID-19 Infections. *Obesity (Silver Spring)*. Jul 2020;28(7):1187-1190.
29. Dickerson RN. The obesity paradox in the ICU: real or not? *Crit Care*. Jun 12 2013;17(3):154.

30. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. Mar 17 2020;323(11):1061-1069.
31. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. Feb 15 2020;395(10223):497-506.
32. Wang K, Zuo P, Liu Y, et al. Clinical and laboratory predictors of in-hospital mortality in patients with COVID-19: a cohort study in Wuhan, China. *Clin Infect Dis*. May 3 2020.
33. Pan D, Cheng D, Cao Y, et al. A Predicting Nomogram for Mortality in Patients With COVID-19. *Front Public Health*. 2020;8:461.
34. Chen R, Liang W, Jiang M, et al. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. *Chest*. Jul 2020;158(1):97-105.
35. Hussman JP. Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention. *Front Pharmacol*. 2020;11:1169.
36. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. *Lancet Respir Med*. Jun 2020;8(6):e46-e47.
37. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost*. Apr 2020;18(4):844-847.
38. Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, Mortality, Bleeding and Pathology Among Patients Hospitalized with COVID-19: A Single Health System Study. *J Am Coll Cardiol*. Aug 24 2020.
39. Moores LK, Tritschler T, Brosnahan S, et al. Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report. *Chest*. Sep 2020;158(3):1143-1163.

40. Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *N Engl J Med*. Jul 17 2020.
41. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. *JAMA*. Sep 2 2020.
42. Writing Committee for the R-CAP1, Angus DC, Derde L, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. *JAMA*. Sep 2 2020.
43. Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19 treatment. Available at: <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment>. Accessed Septmeber 30, 2020.
44. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. *N Engl J Med*. May 22 2020.

Table 1. Comparison of baseline characteristics between COVID19 patients with and without ARDS

	COVID with ARDS	COVID without ARDS	P value
	N=643	N=7,173	
Age, years	69 (60-74)	70 (60-76)	0.02
Sex, n (%)			0.92
Male	613 (95)	6,774 (94)	
Female	30 (5)	30 (6)	
Race, n (%)			0.002
Caucasians	250 (39)	3,297 (46)	
Black	306 (48)	2,958 (41)	
Latinos	85 (13)	904 (12)	
BMI, kg/m²	31 (27-35)	29 (24-33)	<0.001
Smoking history, n(%)	302 (47)	3235 (45)	0.36
Comorbidities, n (%)			
Chronic lung disease	254 (39)	2,914 (41)	0.57
Diabetes mellitus	353 (55)	3,392 (47)	<0.001
Hypertension	504 (78)	5,216 (73)	0.002
Chronic heart disease	232 (36)	2807 (39)	0.13
Heart failure	130 (20)	1,489 (21)	0.74
Chronic kidney disease	179 (28)	1,911 (26)	0.51
Liver cirrhosis	27 (4)	297 (4)	0.94
HIV infection	11 (2)	133 (2)	0.79
Charlson Comorbidity Index	3 (1-5)	3 (1-5)	0.58

Medications on admission, n(%)			
Anticoagulants	237 (37)	3,268 (46)	<0.001
Beta-agonists	100 (16)	1,372 (19)	0.03
Beta-blockers	289 (45)	3,238 (45)	0.92
ACE inhibitors	241 (37)	2,540 (35)	0.29
Statins	427 (66)	4,439 (62)	0.02
Prednisone	31 (5)	243 (3)	0.05

Table 2. Comparison of clinical and laboratory indices between COVID19 patients with and without ARDS

	COVID with ARDS	COVID without ARDS	P value
	N=643	N=7,173	
Signs and Symptoms, n(%)			
Fever	405 (63)	3,652 (51)	<0.001
Cough	181 (28)	1,561 (22)	<0.001
Dyspnea	290 (45)	2,141 (29)	<0.001
Fatigue	76 (12)	1,118 (16)	0.01
Diarrhea	63 (10)	606 (8)	0.24
Laboratory results, n(%)			
WBC, x10 ⁹ /L	6.7 (5.1-8.4)	6.4(4.8-7.8)	0.002
Lymphocytes, x10 ⁹ /L	0.86 (0.59-1.21)	1.0 (0.7-1.43)	<0.001
Hemoglobin, g/L	13.6 (12.1-14.9)	13.3 (11.7-14.6)	0.001
Platelets, x10 ⁹ /L	185 (143-235)	192 (151-245)	0.01
Creatinine, mg/dL	1.3 (1.0-2)	1.2 (0.9-1.6)	<0.001
AST, U/L	44 (29-65)	32 (23-49)	<0.001
ALT, U/L	32 (21-49)	26 (17-40)	<0.001
LDH, U/L	374 (266-532)	267 (199-367)	<0.001
D-Dimer, ug/mL	1.1 (0.46-2.23)	0.7 (0.37-1.47)	<0.001
Ferritin, ng/mL	709 (354-1456)	417 (192-876)	<0.001
CRP, mg/dL	18.1 (8.2-68.5)	11.0 (3.6-41.8)	<0.001

Table 3. Comparison of clinical characteristics of ARDS survivors and ARDS non-survivors

	Alive (N=378)	Deceased (n=265)	P value
Age, years	66 (56-72)	72 (66-77)	<0.001
Sex, n (%)			0.1
Male	356 (94)	257 (97)	
Female	22 (6)	8 (3)	
Race, n (%)			0.13
Caucasians	140 (37)	111 (42)	
Black	179 (28)	127 (48)	
Latinos	58 (15)	27 (10)	
BMI, kg/m ²	30 (26-35)	31 (27-35)	0.3
Comorbidities, n (%)			
COPD	62 (16)	73 (28)	0.21
Diabetes mellitus	156 (41)	198 (74)	0.1
Hypertension	286 (76)	218 (82)	0.05
Chronic heart disease	80 (21)	87 (33)	0.001
Heart failure	52 (14)	57 (22)	0.01
Chronic kidney disease	93 (25)	86 (32)	0.03
Liver cirrhosis	17 (5)	10 (4)	0.65
HIV infection	3 (0.8)	8 (3)	0.03
Charlson Comorbidity Index	2 (1-5)	3 (1-6)	<0.001
Treatment			
Antibiotics	301 (79)	223 (84)	0.32
Beta-agonists	113 (29)	63 (23)	0.08

Remdisivir	156 (41)	63 (24)	<0.001
Corticosteroids	186 (49)	104 (39)	0.01
Hydroxychloroquine	134 (35)	131 (49)	0.19
Anticoagulants	368 (97)	218 (82)	<0.001
IL-6 inhibitor	81 (21)	56 (21)	0.92
Complications			
Septic shock	170 (45)	188 (71)	<0.001
Acute renal failure	224 (59)	219 (83)	<0.001
Acute heart failure	104 (28)	84 (32)	0.25
Acute cerebrovascular accident	13 (3)	6 (2)	0.19

Figure Legends


Figure 1. Forest plot of the odds ratio for independent factors associated with ARDS progression.



Figure 2. Kaplan-Meier survival curves of patients with ARDS who did and did not an anticoagulant.


(log rank test, $p < 0.001$)

Figure 3. Kaplan-Meier survival curves of patients with ARDS classified according to the treatment received.

Figure 4. Forest plot of the hazard ratio for independent factors associated with 30-day mortality from ARDS.







- No corticosteroids or remdesivir
- Corticosteroids
- Remdesivir
- Corticosteroids plus Remdesivir

